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ABSTRACT
Acute invasive pulmonary aspergillosis occurs predominantly in immunocompromised hosts, with
increasing numbers of cases of invasive aspergillosis among patients with chronic obstructive
pulmonary disease (COPD) being reported. Among 13 cases of invasive aspergillosis diagnosed in
COPD patients admitted to the intensive care unit with acute respiratory distress, the only risk factor for
invasive fungal infection was corticosteroid treatment. Invasive aspergillosis should be suspected in
COPD patients receiving steroid treatment who have extensive pulmonary inﬁltrates. Survival depends
on rapid diagnosis and early appropriate treatment. A decrease or interruption of steroid treatment
should be considered as part of the overall therapeutic strategy.
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During the past decade, Aspergillus spp. have
become the most prevalent airborne fungal path-
ogens in developed countries, with a signiﬁcant
increase in invasive aspergillosis being observed
[1]. This opportunistic disease occurs predomin-
antly in immunocompromised hosts, with the
major risk factors being prolonged granulocy-
topenia and long-term steroid treatment. There
are many reasons for the global increase in
patients at risk of developing invasive aspergil-
losis, including the advent of AIDS, an increase in
the use of high-dose chemotherapeutic regimens,
the worldwide practice of solid-organ transplan-
tation, increased use of immunosuppressive ther-
apy in autoimmune diseases, extended survival of
patients related to improvements in supportive
and intensive care, and progress in the treatment
of bacterial and parasitic infections [2].
Aside from these large high-risk groups, many
cases of fatal invasive pulmonary aspergillosis are
reported regularly in patients with chronic
obstructive pulmonary disease (COPD). Such
patients may have increased susceptibility to
fungal invasive infection for several reasons: (1)
structural changes in lung architecture related to
the pulmonary disease; (2) the common use of
long-term or repeated short-term steroid treat-
ments as an additional immunosuppressive factor
[3]; (3) frequent hospitalisation and antibiotic
treatment, leading to exposure to selected fungal
pathogens; and (4) co-morbidity factors such as
alcoholism, diabetes mellitus or malnutrition.
Two autopsy-based studies have shown that
4% of a population of unselected patients who
died in a European modern tertiary-care hospital
had invasive aspergillosis [4,5], and it seems that
c. 30% of cases of invasive aspergillosis remain
undiagnosed and untreated at death. A system-
atic review of the recent literature showed an
overall case fatality rate for invasive aspergillosis
of 58% [6]. Among the 1941 patients studied, 26
(1.3%) had COPD. In another report, dissemin-
ated aspergillosis was documented in six patients
who underwent autopsy; ﬁve (2.7%) had COPD
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[7]. It has been demonstrated that Aspergillus spp.
are among the most frequent microorganisms
causing pulmonary inﬁltrates in patients receiv-
ing long-term glucocorticoid treatment [8]. How-
ever, the true incidence of invasive aspergillosis
in COPD is probably underestimated for several
reasons, including the disparities between risk
groups, the variable durations of exposure, the
fact that invasive aspergillosis is a relatively
uncommon and thus a relatively unknown entity,
the fact that the multiple clinical presentations
require a high degree of suspicion for treatment,
and the fact that, despite advances in diagnostic
procedures, laboratory tests still have a low
sensitivity for this disease.
Table 1 documents our own experience of 13
fatal cases of acute invasive pulmonary aspergil-
losis in COPD patients. All 13 patients were
admitted to the intensive care unit with acute
respiratory failure and severe bronchospasm that
was resistant to treatment. A major observation
was that increasing doses of corticosteroid, related
to persistant bronchospasm, were used within the
intensive care unit, despite the fact that most
patients were diagnosed with invasive aspergil-
losis before death. Corticosteroids impair immune
function, especially the conicidal activity of
human tissue macrophages [9], and are respon-
sible for the monocyte-mediated damage to fungal
hyphae [10]. Moreover, corticosteroids promote
the in-vitro growth of Aspergillus fumigatus [11].
Growth rate is likely to be a key determinant of
pathogenicity, and this effect was shown to be
dose-dependent [12]. Furthermore, a prospective
study of 33 patients receiving long-term glucocor-
ticoid treatment demonstrated that the local and
systemic inﬂammatory response was attenuated
in comparison with the response observed in
patients with pulmonary infections, but without
corticoid treatment, or with treatment for only a
short period (< 9 days) [8]. For the cases shown in
Table 1, the increasing doses of corticoids given to
all patients were the predominant risk factor for
developing invasive aspergillosis, and following
diagnosis, were the major factor in the progression
of mycelial infection. In this category of patients, a
high-dose regimen of steroid anti-inﬂammatory
therapy may be linked to a fatal outcome.
The growing fungal challenge to immunocom-
promised patients has resulted in the develop-
ment of new diagnostic methods, including
serological tests for the detection of Aspergillus
antigen and the use of high-resolution computed
tomography scanning of the chest. Many Euro-
pean centres test high-risk haematology patients
for galactomannan antigen on a weekly basis.
Caillot et al. [13] reported that early computed
tomography scanning, combined with galacto-
mannan antigen detection (followed by surgery
and azole therapy as appropriate), reduced mor-
tality in acute leukaemia patients from 60% to
12% over a period of 6 years [13]. However, the
rapid blood clearance of galactomannan antigen
requires repeated samples for an optimal diagno-
sis, and this may explain the disappointing level
of sensitivity that has been reported [14]. These
new diagnostic tools have been validated only in
cohorts of patients with haematological malig-
nancies, but prospective studies focusing on other
subsets of patients, e.g., those with COPD, are
lacking. For the patients listed in Table 1, tests for
galactomannan antigen were performed only
sporadically when the diagnosis of invasive
aspergillosis was highly suspected. Fewer than
half of the patients had a bronchoscopy or a
computed tomography scan performed; interest-
ingly, sensitivity was 100%.
Several important points can be highlighted
with respect to COPD patients with invasive
aspergillosis. First, the overall epidemiological
data suggest that the incidence of invasive asper-
gillosis in non-haematological patients is under-
estimated, particularly in COPD patients; indeed,
according to post-mortem examinations, fungal
infections are among the most frequently missed
diagnoses. Second, the occurrence of pulmonary
Table 1. Diagnostic and therapeutic approaches used in a














(mg ⁄kg ⁄day) Treatment
1 Sputum + ETA Yes 0 0.9 AmBd
2 ETA + BAL Yes 0 0.9 Itraconazole
3 ETA + BAL No 2 1.6 Voriconazole
4 ETA No 0 1.4 Ambd
5 ETA No 0 1.2 No antifungal
treatment
6 ETA + BAL No 0 0.8 No antifungal
treatment
7 ETA + BAL No 0 1.9 No antifungal
treatment
8 ETA + BAL Yes 1 0.8 AmBd
9 ETA + BAL No 0 1.2 Ambd
10 ETA No 0 1.6 Ambd
11 ETA + BAL No 1 0.7 Ambd
12 ETA No 0 1.1 Ambd
13 ETA + BAL Yes 3 1.1 Ambd
AmBd, amphotericin B deoxycholate; BAL, bronchoalveolar lavage; CT, computed
tomography; ETA, endotracheal aspirates; GM, galactomannan antigen.
428 Clinical Microbiology and Infection, Volume 11 Number 6, June 2005
 2005 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 11, 427–429
inﬁltrates in COPD patients receiving long-term
and ⁄ or high-dose regimens of glucocorticoids
should raise the question of invasive aspergillosis.
In this context, the prolonged use of corticoster-
oids deserves special attention as a major risk
factor for the development and ⁄ or accentuation of
this disease. An interruption of or decrease in
steroid treatment (if possible) seems to be a logical
proposal. The 100% mortality observed for the
cases in Table 1 emphasises that every effort
should be made to obtain an early diagnosis in
order to improve the chance of survival in these
patients. All of the cases described in the litera-
ture have been associated with a fatal outcome.
Therefore, it also seems worthwhile to investigate
the diagnostic procedures for non-haematological
patients in a prospective manner. Post-mortem
examination of patients with COPD who die of
invasive pneumonia should be requested more
often. Prompt treatment remains the critical prog-
nostic factor, and the recent expansion of the
antifungal armamentarium is a cause for opti-
mism. However, this serves only to emphasise the
need to improve prophylactic measures, diagnos-
tic procedures and therapeutic approaches.
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